Trevi Therapeutics (TRVI) Tax Provisions (2018 - 2026)
Trevi Therapeutics (TRVI) posted quarterly Tax Provisions of -$20000.0 for Q1 2026, down 81.82% year-over-year from -$110000.0 in Q1 2025, and up 4.76% quarter-over-quarter from -$21000.0 in Q4 2025.
Powered by 
Analysis
Trevi Therapeutics (TRVI) Tax Provisions (2018 - 2026) Analysis & Trends
Trevi Therapeutics' Tax Provisions history runs 9 years deep, the most recent figure standing at -$20000.0 for Q1 2026.
- In Q1 2026, Tax Provisions fell 81.82% year-over-year to -$20000.0; the TTM figure through Mar 2026 stood at -$77000.0 (up 10.47% YoY), while the FY2025 annual figure was -$69000.0, up 15.85% from the prior year.
- Tax Provisions for Q1 2026 stood at -$20000.0, up from -$21000.0 in the prior quarter.
- The five-year high for Tax Provisions was $18000.0 in Q4 2023, with the low at -$36000.0 in Q4 2024.
- The 5-year median for Tax Provisions is -$13000.0 (2023), against an average of -$14058.8.
- Peak annual rise in Tax Provisions reached 190.0% in 2023, while the deepest fall reached 650.0% in 2023.
- Trevi Therapeutics' Tax Provisions stood at -$20000.0 in 2022, then surged by 190.0% to $18000.0 in 2023, then slumped by 300.0% to -$36000.0 in 2024, then surged by 41.67% to -$21000.0 in 2025, then rose by 4.76% to -$20000.0 in 2026.
- Business Quant data shows TRVI's Tax Provisions at -$20000.0 in Q1 2026, -$21000.0 in Q4 2025, and -$15000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -59.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 15.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.45 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Trevi Therapeutics | 2.71 Bn | 2.71 Bn | - | -19,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -19,000.00 |
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -8.95 Mn |
| Sep 30, 2025 | -15,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | -11,000.00 |
| Dec 31, 2024 | -10.02 Mn |
| Sep 30, 2024 | -31,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -8,000.00 |
| Dec 31, 2023 | 18,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | -7,000.00 |
| Dec 31, 2022 | -20,000.00 |
| Sep 30, 2022 | -7,000.00 |
| Jun 30, 2022 | -4,000.00 |
| Mar 31, 2022 | -5,000.00 |
| Dec 31, 2021 | -6,000.00 |
| Sep 30, 2021 | 2,000.00 |